Reuters logo
BRIEF-BioDelivery sciences announces patent litigation settlement agreement with Teva
October 12, 2017 / 11:14 AM / 11 days ago

BRIEF-BioDelivery sciences announces patent litigation settlement agreement with Teva

Oct 12 (Reuters) - Biodelivery Sciences International Inc

* BioDelivery Sciences announces patent litigation settlement agreement with Teva

* BioDelivery Sciences International Inc - ‍other terms of agreement are confidential​

* BioDelivery Sciences - ‍as part of settlement agreement, co has entered into a non-exclusive license agreement with Teva ​

* BioDelivery Sciences International - ‍ entered into settlement agreement with Teva Pharmaceuticals USA, Actavis Laboratories Ut, Teva Pharmaceuticals Industries

* BioDelivery Sciences International Inc - ‍as part of settlement agreement BDSI has entered into a non-exclusive license agreement with Teva​

* BioDelivery Sciences - settlement agreement permits Teva to first begin selling its generic version of BUNAVAIL in U.S. On July 23, 2028 or earlier under certain circumstances

* BioDelivery Sciences International - ‍ settlement agreement resolves BDSI’s BUNAVAIL patent litigation against Teva pending in United States district court​

* BioDelivery Sciences - ‍agreement with Teva permits Teva to first begin selling generic version of BUNAVAIL in U.S. On July 23, 2028 or earlier​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below